期刊文献+

依维莫司的药动学影响因素及治疗药物监测研究进展 被引量:4

原文传递
导出
摘要 目的:简述依维莫司的作用机制,重点阐述依维莫司的药动学影响因素和治疗药物监测研究进展。方法:查阅近年依维莫司药动学研究文献,提取重要信息,通过分析、归纳进行综述。结果与结论:依维莫司的药动学影响因素主要有饮食、肝功能损害、种族差异、合并用药等,基因多态性、年龄、体质量对其影响不显著。治疗药物监测方法有免疫法和液相色谱法,两种方法相关性已明确。综合考虑依维莫司药动学的影响因素,采用已有的研究结论指导依维莫司个体化给药,可提高疗效,降低不良反应。
出处 《中国药房》 CAS CSCD 2013年第46期4383-4386,共4页 China Pharmacy
  • 相关文献

参考文献26

  • 1Kirchner GI, Meier-Wiedenbach I, Manns MP.Clinical ph- armacokinetics of everolimus[J]. Clin Pharmacokinet, 2004,43(2) :83.
  • 2Alegre C, Jim6nez C, Manrique A, et al. Everolimus mon- otherapy or combined therapy in liver transplantation: indi- cations and results[J].Transplant Proc, 2013,45 (5) : 1 971.
  • 3Dunn C, Croom KF. Everolimus: A review of its use in re- nal and cardiac transplantation[J]. Drug, 2006, 66 (4) : 547.
  • 4O' Donnel A, Faivre S, Burris HA, et al.Phase I pharmaco- kinetic and pharmacodynamic study of the oral mammali- an target of rapamycin in-hibitor everolimus in patients with advanced solid tumors[J]. J Clin Oncol, 2008, 26 (10) : 1 588.
  • 5Kovarik JM, Hsu CH, Mcmahon L, et al. Population phar- macokinetics of everolimus in de novo renal transplant pa- tients: impact of ethnicity and comedications[J]. Clin Pharmacol Ther, 2001,70 (3) : 247.
  • 6van Damme-Lombaerts R, WEBB NA, Hoyer PF, et al. Single-dose pharrnacokinetics and tolerability of everolim- us in stable pediatric renal transplant patients[J]. Pediatr Transplant, 2002,6(2) : 147.
  • 7Pape L, Ganschow R, Ahlenstiel T. Everolimus in pediat- ric transplantation [J].Curr Opin Organ Transplant, 2012, 17(5):515.
  • 8Holdaas H, Midtvedt K,/-sberg A. A drug safety evalua- tion of everolimus in kidney transplantation [J]. Expert Opin DrugSaf,2012,11(6) :1 013.
  • 9Kovarik JM, Bartlett M, Rordorf C, et al. Sotrastaurin and everolimus pharmacokinetics after single-dose coadminis- tration[J].lnt J Clin Pharmacol Ther , 201 O, 48 (2) : 103.
  • 10Urva S, Bouillaud E, Delaney R, et al. A phase I study evaluating the effect of everolimus on the pharmacokinet- its of midazolam in healthy subjects[J] J Clin Pharmacol, 2013,53(4) :444.

同被引文献43

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部